Neximmune Inc (NEXI PINK) stock market data APIs
$0.0001
0(0%)
as of October 28, 2026
Try our APIs with
free plan!
Neximmune Inc Financial Data Overview
Price chart is built with
Anychart
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a vivo directly injectable modality platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It also provides NEXI-004 which is in preclinical stage for EBV related diseases. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
Prev. Close
0.0001
Open
0.0001
High
0.0001
Low
0.0001
52 wk Range
0.0001-0.0003
Market Cap
139
Shares Outstanding
1 395 K
EPS
-1.6856
Beta
3.61
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Neximmune Inc data using free add-ons & libraries
Get Neximmune Inc Fundamental Data
Neximmune Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -16 375 748
- Earnings Per Share: -18
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-08-07
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Neximmune Inc News
New
Is Nexi (BIT:NEXI) Fairly Valued After Its FTSE All World Index Exit?
Nexi (BIT:NEXI) was removed from the FTSE All-World Index (USD) on 19 September 2026, a change that can influence how index-tracking funds and benchmark-aware investors treat the stock. Nexi's share ...
Information relating to the financial conditions of the departure of Mr Jean-Claude Bassien
Nexity INFORMATION RELATING TO THE FINANCIAL CONDITIONS OF THE DEPARTURE OF MR. JEAN-CLAUDE BASSIEN Publication carried out in accordance with the recommendations of the Afep-Medef corporate gover...
CDP opposes Nexi’s sale of majority stake in digital banking unit to TPG
Italy’s Cassa Depositi e Prestiti (CDP) is opposing the payments group Nexi selling a majority stake in its digital banking solutions business to private equity firm TPG, Reuters reported, citing tw...
TPG makes $1.16bn bid for Nexi’s digital banking solutions unit
TPG has submitted a binding offer of approximately €1bn ($1.16bn) for the digital banking solutions division of Italian payments technology (PayTech) company Nexi. The US-based alternative asset ma...
Get Neximmune Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.